Showing results (21-30 of 812) with videos related to

Sort By:
Pageof 82
Critical Reviews in Oncology/Hematology|November 8, 2017
The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trialsSergio Rizzo, Antonio Galvano, Francesco Pantano, et al.
Cancer Treatment Reviews|December 7, 2010
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?Sergio Rizzo, Giuseppe Bronte, Daniele Fanale, et al.
Expert Opinion on Biological Therapy|September 12, 2015
Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?Francesco Passiglia, Giuseppe Bronte, Marta Castiglia, et al.
Scientific Reports|September 8, 2018
The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysisFrancesco Passiglia, Sergio Rizzo, Massimo Di Maio, et al.
Frontiers in Bioscience (Elite Edition)|May 31, 2011
EGFR genomic alterations in cancer: prognostic and predictive valuesGiuseppe Bronte, Marianna Terrasi, Sergio Rizzo, et al.
Cancer Treatment Reviews|December 7, 2010
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinomaGiuseppe Bronte, Sergio Rizzo, Laura La Paglia, et al.
Scientific Reports|November 20, 2018
Publisher Correction: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysisFrancesco Passiglia, Sergio Rizzo, Massimo Di Maio, et al.
Oncotarget|April 16, 2016
Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?Daniele Fanale, Valeria Amodeo, Viviana Bazan, et al.
Oncotarget|January 6, 2017
"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitorsLorena Incorvaia, Francesc Passiglia, Sergio Rizzo, et al.
Current Cancer Drug Targets|March 10, 2018
Metastatic Site Location Influences the Diagnostic Accuracy of ctDNA EGFR- Mutation Testing in NSCLC Patients: a Pooled AnalysisFrancesco Passiglia, Sergio Rizzo, Christian Rolfo, et al.
Pageof 82